Literature DB >> 31250007

Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.

R Knackstedt1, T A Sussman2, L McCahon3, J-M Song2, P Funchain2, B Gastman4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31250007     DOI： 10.1093/annonc/mdz187

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Current concepts and approaches to merkel cell carcinoma.

Authors:  Marianna Babadzhanov; Nicole Doudican; Reason Wilken; Mary Stevenson; Anna Pavlick; John Carucci
Journal:  Arch Dermatol Res       Date:  2020-07-14       Impact factor: 3.017

2.  Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.

Authors:  Martin A Cheever; Suzanne L Topalian; Paul Nghiem; Shailender Bhatia; Evan J Lipson; William H Sharfman; Ragini R Kudchadkar; Andrew S Brohl; Philip A Friedlander; Adil Daud; Harriet M Kluger; Sunil A Reddy; Brian C Boulmay; Adam Riker; Melissa A Burgess; Brent A Hanks; Thomas Olencki; Kari Kendra; Candice Church; Tomoko Akaike; Nirasha Ramchurren; Michi M Shinohara; Bob Salim; Janis M Taube; Erin Jensen; Mizuho Kalabis; Steven P Fling; Blanca Homet Moreno; Elad Sharon
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 3.  Advances in Targeting Cutaneous Melanoma.

Authors:  Dimitri Kasakovski; Marina Skrygan; Thilo Gambichler; Laura Susok
Journal:  Cancers (Basel)       Date:  2021-04-26       Impact factor: 6.639

4.  Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.

Authors:  Michael A Cilento; Oliver Klein; Elizabeth Egan; Rachel Roberts-Thomson
Journal:  Australas J Dermatol       Date:  2022-06-06       Impact factor: 2.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.